The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Open accessAbstract
SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia can directly upregulate the expression of various cellular immune checkpoints (such as programmed cell death‐ligand 1, PD‐L1) in the TME.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Cited by
Sorted by citations
Items 101–200 of 1,001
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Torrejon, D. Y., Abril-Rodriguez, G., Champhekar, A. S., Tsoi, J., Campbell, K. M., Kalbasi, A., Parisi, G., Zaretsky, J. M., Garcia-Diaz, A., Puig-Saus, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1409 · Cited by 146
Alessi, J. V., Ricciuti, B., Spurr, L. F., Gupta, H. V., Li, Y. Y., Glass, C., Nishino, M., Cherniack, A. D., Lindsay, J. R., Sharma, B., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.024 · Cited by 156
The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy
Lai, Y., Tang, F., Huang, Y., He, C., Chen, C., Zhao, J., Wu, W., & He, Z. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29969 · Cited by 140
Shui, L., Ren, H., Yang, X., Li, J., Chen, Z., Cheng, Y., Zhu, H., & Shui, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.570465 · Cited by 150
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Garris, C., & Luke, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1321 · Cited by 146
Zhang, Z., Chen, L., Chen, H., Zhao, J., Li, K., Sun, J., & Zhou, M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104207 · Cited by 135
Hodi, F. S., Wolchok, J. D., Schadendorf, D., Larkin, J., Long, G. V., Qian, X., Saci, A., Young, T. C., Srinivasan, S., Chang, H., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0983 · Cited by 138
Self-citationMechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 135
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Jerby‐Arnon, L., Neftel, C., Shore, M. E., Weisman, H. R., Mathewson, N. D., McBride, M. J., Haas, B. J., Izar, B., Volorio, A., Boulay, G., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01212-6 · Cited by 129
Wu, S., Fukumoto, T., Lin, J., Nacarelli, T., Wang, Y., Ong, D., Liu, H., Fatkhutdinov, N., Zundell, J. A., Karakashev, S. V., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00160-x · Cited by 132
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
Saux, O. L., Ray-Coquard, I. L., & Labidi‐Galy, S. I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.017 · Cited by 127
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
Fukumoto, T., Fatkhutdinov, N., Zundell, J. A., Tcyganov, E. N., Nacarelli, T., Karakashev, S. V., Wu, S., Liu, Q., Gabrilovich, D. I., & Zhang, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1302 · Cited by 127
Bilen, M. A., Shabto, J. M., Martini, D. J., Liu, Y., Lewis, C. M., Collins, H., Akce, M., Kissick, H. T., Carthon, B. C., Shaib, W. L., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6073-7 · Cited by 126
Self-citationStructure of human chromatin-remodelling PBAF complex bound to a nucleosome
Yuan, J., Chen, K., Zhang, W., & Chen, Z. (2022) · Nature · doi:10.1038/s41586-022-04658-5 · Cited by 122
SMARCA4: Current status and future perspectives in non-small-cell lung cancer
Tian, Y., Xu, L., Li, X., Li, H., & Zhao, M. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216022 · Cited by 123
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer
Chabanon, R. M., Morel, D., Eychenne, T., Daage, L. C., Bajrami, I., Dorvault, N., Garrido, M., Meisenberg, C., Lamb, A. E., Duong-Ngo, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0628 · Cited by 120
Chun, H.-J. E., Johann, P. D., Milne, K., Zapatka, M., Büllesbach, A., Ishaque, N., Iskar, M., Erkek, S., Wei, L. L., Tessier‐Cloutier, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.013 · Cited by 117
Predictive biomarkers for response to immune checkpoint inhibition
Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 118
Klümper, N., Ralser, D. J., Bawden, E., Landsberg, J., Zarbl, R., Kristiansen, G., Toma, M. I., Ritter, M., Hölzel, M., Ellinger, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000552 · Cited by 116
Motzer, R. J., Choueiri, T. K., McDermott, D. F., Powles, T. B., Vano, Y. A., Gupta, S. K., Yao, J., Han, G. C., Ammar, R., Papillon‐Cavanagh, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004316 · Cited by 117
Self-citationKoçak, B., Durmaz, E. Ş., Kuş, E. A., & Ulusan, M. B. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.18.20443 · Cited by 120
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Naranbhai, V., Viard, M., Dean, M. C., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P. K., Chin, K. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00582-9 · Cited by 119
Self-citationHenon, C., Blay, J., Massard, C., Mir, O., Bahleda, R., Dumont, S., Postel-Vinay, S. C., Adam, J., Soria, J., & Cesne, A. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz160 · Cited by 113
Gong, D., Zhang, J., Chen, Y., Xu, Y., Ma, J., Hu, G., Yi-ran, H., Zheng, J., Zhai, W., & Xue, W. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1223-y · Cited by 113
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 115
Bai, J., Shi, J., Li, C., Wang, S., Zhang, T., Hua, X., Zhu, B., Koka, H., Wu, H., Song, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21026-5 · Cited by 113
Takada, K., Sugita, S., Murase, K., Kikuchi, T., Oomori, G., Ito, R., Hayasaka, N., Miyanishi, K., Iyama, S., Ikeda, H., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13215 · Cited by 113
Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
Carril-Ajuria, L., Santos, M., Roldán‐Romero, J. M., Rodríguez‐Antona, C., & de Velasco, G. (2019) · Cancers · doi:10.3390/cancers12010016 · Cited by 109
Oka, M., Xu, L., Suzuki, T., Yoshikawa, T., Sakamoto, H., Uemura, H., Yoshizawa, A. C., Suzuki, Y., Nakatsura, T., Ishihama, Y., et al. (2021) · Genome biology · doi:10.1186/s13059-020-02240-8 · Cited by 115
MHC-I genotype and tumor mutational burden predict response to immunotherapy
Goodman, A. M., Castro, A., Pyke, R. M., Okamura, R., Kato, S., Riviere, P. J., Frampton, G. M., Sokol, E. S., Zhang, X., Ball, E. D., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00743-4 · Cited by 112
Coulton, A., Murai, J., Qian, D., Thakkar, K., Lewis, C. E., & Litchfield, K. (2024) · Nature Communications · doi:10.1038/s41467-024-49885-8 · Cited by 125
Naito, T., Udagawa, H., Umemura, S., Sakai, T., Zenke, Y., Kirita, K., Matsumoto, S., Yoh, K., Niho, S., Tsuboi, M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.009 · Cited by 106
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
Lu, M., Zhao, B., Liu, M., Wu, L., Li, Y., Zhai, Y., & Shen, X. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00193-0 · Cited by 113
The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
Chen, H., Chong, W., Teng, C., Yao, Y., Wang, X., & Li, X. (2019) · Cancer Science · doi:10.1111/cas.14113 · Cited by 106
An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles
Li, M., Zhang, Z., Li, L., & Wang, X. (2020) · Communications Biology · doi:10.1038/s42003-020-01230-7 · Cited by 100
Epigenetic modifiers as new immunomodulatory therapies in solid tumours
Aspeslagh, S., Morel, D., Soria, J., & Postel-Vinay, S. C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy050 · Cited by 105
Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
Adashek, J. J., Subbiah, V., & Kurzrock, R. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.08.009 · Cited by 99
Naito, T., Umemura, S., Nakamura, H., Zenke, Y., Udagawa, H., Kirita, K., Matsumoto, S., Yoh, K., Niho, S., Motoi, N., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13070 · Cited by 98
Labriola, M., Zhu, J., Gupta, R. T., McCall, S. J., Jackson, J., Kong, E., White, J. R., Cerqueira, G. C., Gerding, K., Simmons, J. K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000319 · Cited by 97
McGrail, D. J., Federico, L., Li, Y., Dai, H., Lu, Y., Mills, G. B., Yi, S. S., Lin, S., & Sahni, N. (2018) · Nature Communications · doi:10.1038/s41467-018-03730-x · Cited by 102
Epigenetic modifiers: activities in renal cell carcinoma
de Cubas, A. A., & Rathmell, W. K. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0052-7 · Cited by 97
Xiong, D., Wang, Y., Singavi, A. K., Mackinnon, A. C., George, B., & You, M. (2018) · iScience · doi:10.1016/j.isci.2018.10.021 · Cited by 94
Wang, X., Lamberti, G., Federico, A. D., Alessi, J. V., Ferrara, R., Sholl, M. L., Awad, M. M., Vokes, N. I., & Ricciuti, B. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.03.007 · Cited by 99
Soldi, R., Ghosh, T., Weston, A., Thode, T. G., Drenner, K., Lewis, R., Kaadige, M. R., Srivastava, S., Ampanattu, S. D., del Villar, R. R., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235705 · Cited by 94
Boilève, A., Carlo, M. I., Barthélémy, P., Oudard, S. M., Borchiellini, D., Voss, M. H., George, S., Chevreau, C., Landman‐Parker, J., Tabone, M.-D., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0482-z · Cited by 93
Self-citationWu, Y., Zhang, L., He, S., Guan, B., He, A., Yang, K., Gong, Y., Li, X., & Zhou, L. (2020) · Aging · doi:10.18632/aging.104115 · Cited by 92
Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis
Zhou, W., Liu, H., Yuan, Z., Zundell, J. A., Towers, M., Lin, J., Lombardi, S., Nie, H., Murphy, B., Yang, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.002 · Cited by 99
Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion
Li, F., Kitajima, S., Kohno, S., Yoshida, A., Tange, S., Sasaki, S., Okada, N., Nishimoto, Y., Muranaka, H., Nagatani, N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3604 · Cited by 91
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R. O., Palucka, K., Samayoa, J. A., Spranger, S., Warren, S. E., Wong, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0602-4 · Cited by 90
Self-citationIntrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer
Gurjao, C., Liu, D., Hofree, M., AlDubayan, S. H., Wakiro, I., Su, M.-J., Felt, K. D., Gjini, E., Brais, L. K., Rotem, A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0683 · Cited by 92
Self-citationWood, M. A., Weeder, B. R., David, J. K., Nellore, A., & Thompson, R. F. (2020) · Genome Medicine · doi:10.1186/s13073-020-00729-2 · Cited by 94
Molecular alterations in meningioma: prognostic and therapeutic perspectives
Birzu, C., Peyre, M., & Sahm, F. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000687 · Cited by 90
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 94
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 90
Mapping genomic and epigenomic evolution in cancer ecosystems
Ushijima, T., Clark, S. J., & Tan, P. B. O. (2021) · Science · doi:10.1126/science.abh1645 · Cited by 89
Kang, J., Lee, J. H., Cha, H., An, J., Kwon, J., Lee, S., Kim, S., Baykan, M. Y., Kim, S. Y., An, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48310-4 · Cited by 90
Mutations in renal cell carcinoma
D’Avella, C. A., Abbosh, P. H., Pal, S. K., & Geynisman, D. M. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.10.027 · Cited by 89
Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy
Biasi, S. D., Gibellini, L., Tartaro, D. L., Puccio, S., Rabacchi, C., Mazza, E. M. C., Brummelman, J., Williams, B., Kaihara, K. A., Forcato, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21928-4 · Cited by 89
Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy
Zhou, B., Liu, J., Lin, M., Zhu, J., & Chen, W. R. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214009 · Cited by 86
Samartzis, E. P., Labidi‐Galy, S. I., Moschetta, M., Uccello, M., Kalaitzopoulos, D. R., Fidalgo, J. A. P., & Boussios, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3022a · Cited by 83
Guo, L., Wei, R., Lin, Y., & Kwok, H. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01508 · Cited by 85
Leveraging big data of immune checkpoint blockade response identifies novel potential targets
Barèche, Y., Kelly, D., Aghababazadeh, F. A., Nakano, M., Esfahani, P. N., Tkachuk, D., Mohammad, H., Samstein, R. M., Lee, C., Morris, L. G. T., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.084 · Cited by 85
Giorgi, U. D., Cartenì, G., Giannarelli, D., Basso, U., Galli, L., Cortesi, E., Caserta, C., Pignata, S., Sabbatini, R., Bearz, A., et al. (2018) · British Journal of Urology · doi:10.1111/bju.14461 · Cited by 85
Carretero-González, A., Lora, D., Martín-Sobrino, I., Sanz, I. S., Bourlon, M. T., Herranz, U. A., Chanzá, N. M., Castellano, D., & de Velasco, G. (2020) · Cancers · doi:10.3390/cancers12071945 · Cited by 84
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma
Flippot, R., Escudier, B. J., & Albiges, L. K. (2018) · Drugs · doi:10.1007/s40265-018-0970-y · Cited by 79
Terry, S., Dalban, C., Rioux-Leclercq, N. C., Adam, J., Meylan, M., Buart, S., Bougoüin, A., Lespagnol, A., Dugay, F., Moreno, I. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0972 · Cited by 85
Context-specific functions of chromatin remodellers in development and disease
Gourisankar, S. P., Krokhotin, A., Wenderski, W., & Crabtree, G. R. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00666-x · Cited by 88
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 78
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Adashek, J. J., Kato, S., Ferrara, R., Russo, G. L., & Kurzrock, R. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0636 · Cited by 82
Dizman, N., Hsu, J., Bergerot, P. G., Gillece, J. D., Folkerts, M., Reining, L., Trent, J., Highlander, S. K., & Pal, S. K. (2021) · Cancer Medicine · doi:10.1002/cam4.3569 · Cited by 78
Zhai, W., Ma, J., Zhu, R., Chen, X., Zhang, J., Chen, Y., Chen, Z., Gong, D., Zheng, J., Chen, C., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0196-5 · Cited by 78
Fouassier, L., Marzioni, M., Afonso, M. B., Dooley, S., Gaston, K., Giannelli, G., Rodrigues, C. M. P., Lozano, E., Mancarella, S., Segatto, O., et al. (2019) · Liver International · doi:10.1111/liv.14102 · Cited by 79
Friedman, C. F., Snyder, A., Zhou, Q. C., Carducci, M. A., de Meritens, A. B., Corr, B. R., Fu, S., Hollmann, T. J., Iasonos, A. E., Konner, J. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001126 · Cited by 78
Self-citationCombinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
Lee, J. V., Housley, F., Yau, C. S. F., Nakagawa, R. M., Winkler, J., Anttila, J. M., Munne, P., Savelius, M., Houlahan, K. E., de Mark, D. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31238-y · Cited by 81
Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma
Cotta, B. H., Choueiri, T. K., Cieslik, M. P., Ghatalia, P., Mehra, R., Morgan, T. M., Palapattu, G. S., Shuch, B. M., Vaishampayan, U. N., Allen, E. M. V., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.04.003 · Cited by 84
Self-citationZhu, Z., Jin, Y., Zhou, J., Chen, F., Chen, M., Gao, Z., Hu, L., Xuan, J., Li, X., Song, Z., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02059-y · Cited by 87
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
Alaiwi, S. A., Nassar, A. H., Xie, W., Bakouny, Z., Berchuck, J. E., Braun, D. A., Baca, S. C., Nuzzo, P. V., Flippot, R., Mouhieddine, T. H., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0866 · Cited by 80
Self-citationBao, R., Stapor, D. C., & Luke, J. J. (2020) · Genome Medicine · doi:10.1186/s13073-020-00787-6 · Cited by 80
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 78
Signoretti, S., Flaifel, A., Chen, Y., & Reuter, V. E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2259 · Cited by 76
Self-citationBihr, S., Ohashi, R., Moore, A. L., Rüschoff, J. H., Beisel, C., Hermanns, T., Mischo, A., Corrò, C., Beyer, J., Beerenwinkel, N., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2018.12.006 · Cited by 82
Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
Kim, M., Jin, Z., Kolb, R. H., Borcherding, N. C., Chatzkel, J. A., Falzarano, S. M., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13225856 · Cited by 80
Comprehensive assessment of cellular senescence in the tumor microenvironment
Wang, X., Ma, L., Pei, X., Wang, H., Tang, X., Pei, J.-F., Ding, Y.-N., Qu, S., Wei, Z.-Y., Wang, H.-Y., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac118 · Cited by 76
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
Raimondi, A., Sepe, P., Zattarin, E., Mennitto, A., Stellato, M., Claps, M., Guadalupi, V., Verzoni, E., de Braud, F., & Procopio, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01644 · Cited by 76
Wang, T.-Y., Liu, Q., Ren, Y., Alam, S. K., Wang, L., Zhu, Z., Hoeppner, L. H., Dehm, S. M., Cao, Q., & Yang, R. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.028 · Cited by 77
Takamatsu, K., Tanaka, N., Hakozaki, K., Takahashi, R., Teranishi, Y., Murakami, T., Kufukihara, R., Niwa, N., Mikami, S., Shinojima, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25865-0 · Cited by 76
The Role of DNA Methylation in Renal Cell Carcinoma
Lasseigne, B. N., & Brooks, J. D. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0337-9 · Cited by 75
Chen, D., Chen, W., Xu, Y., Zhu, M., Xiao, Y., Shen, Y., Zhu, S., Cao, C., & Xu, X. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105454 · Cited by 73
RetractedBiomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 74
Hagiwara, M., Fushimi, A., Yamashita, N., Bhattacharya, A., Rajabi, H. N., Long, M. D., Yasumizu, Y., Oya, M., Liu, S., & Kufe, D. W. (2021) · Oncogene · doi:10.1038/s41388-021-01899-y · Cited by 73
Gupta, S., Cheville, J. C., Jungbluth, A. A., Zhang, Y., Zhang, L., Chen, Y., Tickoo, S. K., Fine, S. W., Gopalan, A., Al‐Ahmadie, H. A., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0269-x · Cited by 73
SWI / SNF ‐deficiency defines highly aggressive undifferentiated endometrial carcinoma
Tessier‐Cloutier, B., Coatham, M. L., Carey, M. S., Nelson, G. S., Hamilton, S. N., Lum, A. M., Soslow, R. A., Stewart, C. J. R., Postovit, L.-M. M., Köbel, M., et al. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.188 · Cited by 72
Immuno-transcriptomic profiling of extracranial pediatric solid malignancies
Brohl, A. S., Sindiri, S., Wei, J. S., Milewski, D., Chou, H.-C., Song, Y. K., Wen, X., Kumar, J., Reardon, H. V., Mudunuri, U. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110047 · Cited by 71
Manning‐Geist, B. L., Liu, Y. L., Devereaux, K. A., Paula, A. D. C., Zhou, Q. C., Ma, W., Selenica, P., Ceyhan‐Birsoy, O., Moukarzel, L. A., Hoang, T. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0713 · Cited by 75
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
Botta, G. P., Kato, S., Patel, H., Fanta, P. T., Lee, S., Okamura, R., & Kurzrock, R. (2021) · JCI Insight · doi:10.1172/jci.insight.150453 · Cited by 71
Sheng, X., Chen, H., Hu, B., Yao, X., Liu, Z., Yao, X., Guo, H., Hu, Y., Ji, Z., Luo, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2210 · Cited by 74
Ballesteros, P. Á., Chamorro, J., Román, M. S., Pozas, J., Santos, V. G. D., Granados, Á. R., Grande, E., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2021) · Cancers · doi:10.3390/cancers13235981 · Cited by 74
Soluble PD-L1 as an early marker of progressive disease on nivolumab
Mahoney, K. M., Ross‐Macdonald, P., Yuan, L., Song, L., Veras, E., Wind‐Rotolo, M., McDermott, D. F., Hodi, F. S., Choueiri, T. K., & Freeman, G. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003527 · Cited by 72
Self-citation
Metadata
- Authors
- Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., Horak, C., Wind-Rotolo, M., Tracy, A., Giannakis, M., Hodi, F. S., Drake, C. G., Ball, M. W., Allaf, M. E., Snyder, A., Hellmann, M. D., Ho, T., Motzer, R. J., Signoretti, S., Kaelin, W. G., Choueiri, T. K., & Van Allen, E. M.
- Affiliations
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb, New York, NY 10154, USA.
- Columbia University Irving Medical Center (US)
- Johns Hopkins University (US)
- Mayo Clinic in Arizona (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Choueiri, Toni K.
- ORCID
- Miao, Diana
- Margolis, Claire A.
- Gao, Wenhua
- Voss, Martin H.
- Li, Wei
- Martini, Dylan J.
- Bossé, Dominick
- Wind-Rotolo, Megan
- Tracy, Adam
- Giannakis, Marios
- Hodi, Frank Stephen
- Drake, Charles G.
- Ball, Mark W.
- Allaf, Mohamad E.
- Snyder, Alexandra
- Hellmann, Matthew D.
- Ho, Thai
- Motzer, Robert J.
- Signoretti, Sabina
- Kaelin, William G.
- Choueiri, Toni K.
- Van Allen, Eliezer M.
- Venue
- Science
- Published
- 2018-02-16
- Volume
- 359
- Issue
- 6377
- Pages
- 801-806
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6035749
- OpenAlex
- W2782183686
- Cited by
- 1,249
- References
- 57
- Citations by year
- 2026: 73 · 2025: 93 · 2024: 153 · 2023: 164 · 2022: 186 · 2021: 195 · 2020: 179 · 2019: 113 · 2018: 89
- FWCI
- 54.48
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (K08 CA188615, U24CA224316)
- Howard Hughes Medical Institute (Medical Research Fellowship)
- American Association for Cancer Research (KureIt Grant for Kidney Research)
- NIH Office of the Director (P30 CA008748)
- Bristol-Myers Squibb (II-ON Consortium)
- Dana-Farber Cancer Institute (Loker Pinard Funds for Kidney Cancer Research)
- Dana-Farber/Harvard Cancer Center (Kidney SPORE)
- BroadNext10
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- clear cell renal cell carcinoma, immune checkpoint inhibitors, SWI/SNF complex, PBRM1 mutation, tumor response prediction, antitumor immunity, interferon-gamma, T cell-mediated killing, metastatic renal cell carcinoma, cancer genomics
- MeSH terms
- Carcinoma, Renal Cell, Chromosomal Proteins, Non-Histone, Humans, Immunotherapy, Kidney Neoplasms, Mutation, Transcription Factors, Cohort Studies, Gene Expression Profiling, Genomics, Exome, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
